FDA Heads Into Uncharted Territory Of ‘Biosimiliar’ Drugs
Under a new process set out by the health law, the FDA approved the first so-called biosimilar drug for sale in the U.S. It’s a copy of the cancer medicine Neupogen that will be sold under the brand name Zarxio.